Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes

被引：8
作者：
Papazafiropoulou, Athanasia K. [1 ,2 ]
Melidonis, Andreas [3 ]
Antonopoulos, Stavros [1 ,2 ]
机构：
[1] Tzaneio Gen Hosp Piraeus, Dept Internal Med 1, 1 Zanni & Afentouli St, Piraeus 18536, Greece
[2] Tzaneio Gen Hosp Piraeus, Diabet Ctr, 1 Zanni & Afentouli St, Piraeus 18536, Greece
[3] Etropolitan Hosp, Diabet & Cardiometab Ctr, Piraeus, Greece
来源：
CURRENT PHARMACEUTICAL DESIGN | 2021年 / 27卷 / 08期
关键词：
Non-diabetic; SGLT2; inhibitors; GLP-1 receptor agonists; empagliflozin; dapagliflozin; canagliflozin; liraglutide; dulaglutide; exenatide; semaglutide; ONCE-WEEKLY SEMAGLUTIDE; DOUBLE-BLIND; CARDIOVASCULAR OUTCOMES; HEART-FAILURE; BODY-WEIGHT; EXENATIDE TREATMENT; NA+/H+ EXCHANGER; GLYCEMIC CONTROL; SGLT2; INHIBITOR; KIDNEY-DISEASE;
D O I：
10.2174/1381612826666200909142126
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
During the last decade, the results of large-scale, randomized, clinical trials on newer antidiabetic agents, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter type 2 (SGLT2) inhibitor, have been published showing promising findings on cardiovascular and renal outcomes. Besides improving glycemic control, GLP-1 receptor agonists have been shown to modify cardiovascular risk factors, such as insulin resistance, body weight, blood pressure (BP), and lipid profile. Additionally, SGLT2 inhibitors except for glycemic control have been shown to induce weight loss and decrease BP. However, there are limited data regarding their effect on patients without diabetes. Therefore, the aim of the present review is to summarize the existing literature data regarding the effects of newer antidiabetic therapies on patients without diabetes.
引用
收藏
页码：1035 / 1042
页数：8
相关论文
共 77 条
  • [1] Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure
    Abraham, William T.
    Ponikowski, Piotr
    Brueckmann, Martina
    Zeller, Cordula
    Macesic, Hemani
    Peil, Barbara
    Brun, Michele
    Ustyugova, Anastasia
    Jamal, Waheed
    Salsali, Afshin
    Lindenfeld, Joann
    Anker, Stefan D.
    Abraham, William
    Anker, Stefan
    Lindenfeld, Joann
    Ponikowski, Piotr
    Brueckmann, Martina
    Salsali, Afshin
    Welty, Francine
    Clayton, Tim
    Greenberg, Barry
    Konstam, Marvin
    Lees, Kennedy
    Palmer, Mike
    Parhofer, Klaus
    Pedersen, Terje
    Carson, Peter
    Freston, James
    Kaplowitz, Neil
    Lewis, James
    Mann, Johannes
    Petrie, John
    Agostoni, Piergiuseppe
    Butler, Javed
    Desai, Akshay
    Filippatos, Gerasimos
    Howlett, Jonathan
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (07) : 932 - 942
  • [2] Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
    Ahren, Bo
    Masmiquel, Luis
    Kumar, Harish
    Sargin, Mehmet
    Karsbol, Julie Derving
    Jacobsen, Sanja Hald
    Chow, Francis
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (05) : 341 - 354
  • [3] Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes
    Al-Jobori, Hussein
    Daniele, Giuseppe
    Cersosimo, Eugenio
    Triplitt, Curtis
    Mehta, Rucha
    Norton, Luke
    DeFronzo, Ralph A.
    Abdul-Ghani, Muhammad
    [J]. DIABETES, 2017, 66 (07) : 1999 - 2006
  • [4] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
    Armstrong, Matthew James
    Gaunt, Piers
    Aithal, Guruprasad P.
    Barton, Darren
    Hull, Diana
    Parker, Richard
    Hazlehurst, Jonathan M.
    Guo, Kathy
    Abouda, George
    Aldersley, Mark A.
    Stocken, Deborah
    Gough, Stephen C.
    Tomlinson, Jeremy W.
    Brown, Rachel M.
    Huebscher, Stefan G.
    Newsome, Philip N.
    [J]. LANCET, 2016, 387 (10019) : 679 - 690
  • [5] Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
    Aroda, Vanita R.
    Bain, Stephen C.
    Cariou, Bertrand
    Piletic, Milivoj
    Rose, Ludger
    Axelsen, Mads
    Rowe, Everton
    DeVries, J. Hans
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (05) : 355 - 366
  • [6] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    Astrup, A.
    Carraro, R.
    Finer, N.
    Harper, A.
    Kunesova, M.
    Lean, M. E. J.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Rossner, S.
    Savolainen, M. J.
    Van Gaal, L.
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 843 - 854
  • [7] Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
    Astrup, Arne
    Rossner, Stephan
    Van Gaal, Luc
    Rissanen, Aila
    Niskanen, Leo
    Al Hakim, Mazin
    Madsen, Jesper
    Rasmussen, Mads F.
    Lean, Michael E. J.
    [J]. LANCET, 2009, 374 (9701) : 1606 - 1616
  • [8] Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
    Baartscheer, Antonius
    Schumacher, Cees A.
    Wust, Rob C. I.
    Fiolet, Jan W. T.
    Stienen, Ger J. M.
    Coronel, Ruben
    Zuurbier, Coert J.
    [J]. DIABETOLOGIA, 2017, 60 (03) : 568 - 573
  • [9] Canagliflozin: Effects in Overweight and Obese Subjects Without Diabetes Mellitus
    Bays, Harold E.
    Weinstein, Richard
    Law, Gordon
    Canovatchel, William
    [J]. OBESITY, 2014, 22 (04) : 1042 - 1049
  • [10] Does Dapagliflozin Affect Energy Intake and Appetite? A Randomized, Controlled Exploratory Study in Healthy Subjects
    Bertran, Elizabeth
    Berlie, Helen D.
    Nixon, Aaron
    Jaber, Linda
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (01): : 119 - 125
12345678